| 发明名称 | Compositions and methods for treatment of cancer | ||
| 摘要 | The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | ||
| 申请公布号 | US9518123(B2) | 申请公布日期 | 2016.12.13 |
| 申请号 | US201614997042 | 申请日期 | 2016.01.15 |
| 申请人 | The Trustees of the University of Pennsylvania | 发明人 | June Carl H.;Levine Bruce L.;Porter David L.;Kalos Michael D.;Milone Michael C. |
| 分类号 | C12N5/071;C12N5/0783;C12N5/22;C07K16/28;A61K35/17;A61K39/00;A61K39/395;C12N15/85;C07K14/705;A61K48/00;C07K14/525;C07K14/725;C07K16/30;C12N7/00;A61K38/17;A61K45/06 | 主分类号 | C12N5/071 |
| 代理机构 | Saul Ewing LLP | 代理人 | Saul Ewing LLP ;Doyle Kathryn |
| 主权项 | 1. A human T cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain comprising, from the amino to the carboxy terminus, a light chain variable region and a heavy chain variable region of SEQ ID NO:20, wherein the CAR further comprises a transmembrane domain, a 4-1BB costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cells is from a human having cancer. | ||
| 地址 | Philadelphia PA US | ||